Novartis Reports Phase 2 Data for Cemiplimab in Urothelial carcinoma

Novartis today announced Phase 2 results for cemiplimab in patients with urothelial carcinoma. The study demonstrated that cemiplimab reduces disease progression risk compared to standard of care or placebo. These results provide important insights into the treatment of urothelial carcinoma and support the continued development of cemiplimab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.